NasdaqGS:ALKSBiotechs
Is Alkermes (ALKS) Building a Durable Sleep-Disorder Franchise With Its Brilliance Phase 3 Bet?
In early April 2026, Alkermes plc announced it had begun the Brilliance phase 3 program, a set of randomized, double-blind, placebo-controlled studies testing its oral orexin 2 receptor agonist alixorexton in adults with narcolepsy type 1 and type 2, following earlier phase 1 and phase 2 work and Breakthrough Therapy designation in narcolepsy type 1.
The launch of these Brilliance Studies signals Alkermes’ intention to build a differentiated sleep-disorder franchise around orexin agonism,...